Many studies have demonstrated that B7-H3 expression is aberrant on a variety of tumor tissues, with high expression correlated to the progression and poor prognosis for patients with cancer [14]–[19], suggesting that B7-H3 expression level may be used as a biomarker for cancers [20], [21]. This evidence concerns the gene CD276 and cancer.